Document:

Exhibit 10.8

 

SUBSCRIPTION AGREEMENT

 

Arcimoto, Inc.

2034 West 2nd Avenue

Eugene, Oregon 97402

 

Ladies and Gentlemen:

 

The undersigned (the “Investor”) hereby
confirms its agreement with Arcimoto, Inc., an Oregon corporation (the “Company”), as follows:

 

1. This
Subscription Agreement, including the Terms and Conditions For Purchase of Shares attached hereto as Annex A (collectively, this
“Agreement”) is made as of the date set forth below between the Company and the Investor.

 

2. The
Company has authorized the sale and issuance to investors of up to an aggregate of 2,500,000 authorized and unissued shares (the
“Shares”) of its common stock, no par value per share. Each Investor will receive Shares at an offering
price equal to the higher of $3.00 or the closing price of our common stock on the NASDAQ Capital Market on November 16, 2018 (the
“Purchase Price”). The Purchase Price as of the date of this Agreement is $3.00 per Share.

 

3. The
offering and sale of the Shares (the “Offering”) are being made pursuant to (i) an effective Registration
Statement on Form S-3, File No. 333-227683 (the “Registration Statement”) filed by the Company with the
Securities and Exchange Commission (the “SEC”) (including the prospectus contained therein) and (2) a
preliminary prospectus supplement dated as of November 16, 2018, and any other prospectus supplement we may file with the SEC,
containing certain supplemental information regarding the Shares and terms of the Offering that has been or will be filed
with the SEC and made available to the Investor.

 

4. The
Company and the Investor agree that at the Closing (as defined in Section 3.1 of Annex A), the Investor will purchase from
the Company and the Company will issue and sell to the Investor the Shares set forth below for the aggregate Purchase Price set
forth below. The Shares shall be purchased pursuant to the Terms and Conditions for Purchase of Shares attached hereto as Annex
A and incorporated herein by this reference as if fully set forth herein. The Investor acknowledges that the Offering
is not being underwritten by any placement agent and that there is no minimum offering amount.

 

5. The
Shares purchased by the Investor will be registered directly on the Company’s records in book-entry form through the facilities
of The Depository Trust Company’s Direct Registration System (DRS) in accordance with the instructions set forth on the signature
page attached hereto.

 

NO LATER THAN 5:00 P.M. EST ON MONDAY,
NOVEMBER 19, 2018, THE INVESTOR SHALL REMIT BY WIRE TRANSFER THE AMOUNT OF FUNDS EQUAL TO THE AGGREGATE PURCHASE PRICE FOR THE
SHARES BEING PURCHASED BY THE INVESTOR TO THE FOLLOWING ACCOUNT:

 

[To be separately provided to the Investor]

 

     

     

    

 

IT IS THE INVESTOR’S RESPONSIBILITY TO MAKE THE NECESSARY
WIRE TRANSFER IN A TIMELY MANNER. IF THE INVESTOR DOES NOT DELIVER THE AGGREGATE PURCHASE PRICE FOR THE SHARES OR DOES NOT PROVIDE
THE REQUIRED INFORMATION FOR DRS SETTLEMENT BY 5:00 P.M. EST ON MONDAY, NOVEMBER 19, 2018, THE SHARES MAY NOT BE DELIVERED
TO THE INVESTOR WITHIN THREE TRADING DAYS OR THE INVESTOR MAY BE EXCLUDED FROM PARTICIPATING IN THE OFFERING ALTOGETHER.

 

6. The
Investor represents that, except as set forth below, (a) it has had no position, office or other material relationship within the
past three years with the Company or persons known to it to be affiliates of the Company, (b) it is not a member of the Financial
Industry Regulatory Authority, Inc. (“FINRA”) or an Associated Person (as such term is defined under
the FINRA’s NASD Membership and Registration Rules Section 1011) as of the Closing, and (c) neither the Investor nor
any group of Investors (as identified in a public filing made with the SEC) of which the Investor is a part in connection with
the Offering, acquired, or obtained the right to acquire, 20% or more of the Company’s common stock (or securities convertible
into or exercisable for common stock) or the voting power of the Company on a post-transaction basis. Exceptions:

 

 

 

(If no exceptions, write “none.”
If left blank, response will be deemed to be “none.”)

 

7. The
Investor represents that it has had access to (i) the prospectus, dated Ocotber 17, 2018, which is a part of the Company’s
Registration Statement, and the documents incorporated by reference therein, (ii) the preliminary prospectus supplement dated November
16, 2018, and the documents incorporated by reference therein, and (iii) any additional prospectus supplement the Company
has filed in connection with the Offering with the SEC (collectively, the “Disclosure Package”), prior
to or in connection with the receipt of this Agreement.

 

8. No
offer by the Investor to buy Shares will be accepted and no part of the Purchase Price will be delivered to the Company until the
Company has accepted such offer by countersigning a copy of this Agreement, and any such offer may be withdrawn or revoked, without
obligation or commitment of any kind, at any time prior to the Company sending (in writing or by electronic mail) notice of its
acceptance of such offer. An indication of interest will involve no obligation or commitment of any kind until this Agreement
is accepted and countersigned by or on behalf of the Company.

 

     

     

    

 

Number of
Shares: _____________________

 

Aggregate Purchase Price: $____________________

 

DRS ELECTRONIC BOOK ENTRY CONFIRMATION Delivery Instructions:

 

Name in which Shares should be issued: ______________________

 

Tax ID Number for the Investor, if applicable: ______________________

 

DRS Account Number for the Investor, if applicable: ______________________

 

Address for Shareholder Communications:

 

Street: _________________________________________

 

City/State/Zip: _________________________________

 

Attention: _____________________________________

 

Telephone No.: _____________________________

 

Please confirm that the
foregoing correctly sets forth the agreement between us by signing in the space provided below for that purpose.

 

	 	Dated as of: ●, 2018
	 	 
	 	 
	 	INVESTOR
	 	 
	 	By:	 
	 	Print Name: 	 
	 	Title:	 

 

Agreed and Accepted

this ● day of ●, 2018:

 

ARCIMOTO, INC.

 

	By:	            	 
	 	Title:	 

 

     

     

    

 

ANNEX A

 

TERMS
AND CONDITIONS FOR PURCHASE OF SHARES

 

1. Authorization
and Sale of the Shares. Subject to the terms and conditions of this Agreement, the Company has authorized the sale of the Shares.

 

2. Agreement
to Sell and Purchase the Shares.

 

2.1 At
the Closing (as defined in Section 3.1), the Company will sell to the Investor, and the Investor will purchase from the
Company, upon the terms and conditions set forth herein, the number of Shares set forth on the last page of the Agreement
to which these Terms and Conditions for Purchase of Shares are attached as Annex A (the “Signature Page”)
for the aggregate purchase price therefor set forth on the Signature Page.

 

2.2 The
Company proposes to enter into substantially this same form of Subscription Agreement with other investors (the “Other
Investors”) and expects to complete sales of Shares to them. The Investor and the Other Investors are hereinafter
sometimes collectively referred to as the “Investors,” and this Agreement and the Subscription
Agreements executed by the Other Investors are hereinafter sometimes collectively referred to as the “Agreements.”

 

3. Closings
and Delivery of the Shares and Funds.

 

3.1 Closing.
The completion of the purchase and sale of the Shares by the Investor (the “Closing”) shall occur
within three trading days after the Company has received full payment for the aggregate purchase price of the Shares to be purchased
by the Investor, at a place and time to be specified by the Company. At the Closing, the Company shall cause Computershare
Trust Company, N.A., the Company’s “Transfer Agent”, to register directly on the Company’s
records in book-entry form through the facilities of The Depository Trust Company’s Direct Registration System (DRS) the
number of Shares purchased by the Investor as set forth on the Signature Page.

 

3.2 Conditions
to the Obligations of the Parties. 

 

(a) Conditions
to the Company’s Obligations. The Company’s obligation to issue and sell the Shares to the Investor shall be
subject to: (i) the receipt by the Company of the purchase price for the Shares being purchased hereunder as set forth on the
Signature Page by 5:00 p.m. EST on Monday, November 19, 2018, and (ii) the accuracy of the representations and warranties made
by the Investor and the fulfillment of those undertakings of the Investor to be fulfilled prior to Closing.

 

(b) Conditions
to the Investor’s Obligations. The Investor’s obligation to purchase the Shares will be subject to the
accuracy of the representations and warranties made by the Company and the fulfillment of those undertakings of the Company to
be fulfilled prior to Closing.

 

3.3 Delivery
of Funds. The Investor shall remit by wire transfer the amount of funds equal to the aggregate purchase price for the Shares
being purchased by the Investor by 5:00 p.m. EST on Monday, November 19, 2018 to the following account designated by the Company:

 

[To be separately provided to the Investor]

 

     

     

    

 

3.4 Delivery
of Shares. No later than three trading days after the execution of this Agreement by the Investor and the Company, the
Shares will be registered directly on the Company’s records in book-entry form through DRS in accordance with the instructions
set forth on the signature page attached hereto.

 

4. Representations,
Warranties and Covenants of the Investor.

 

The Investor acknowledges, represents and
warrants to, and agrees with, the Company that:

 

4.1 The
Investor (a) is knowledgeable, sophisticated and experienced in making, and is qualified to make decisions with respect to, investments
in securities presenting an investment decision like that involved in the purchase of the Shares, including investments in
securities issued by the Company and investments in comparable companies, and (b) in connection with its decision to purchase the
Shares set forth on the Signature Page, has received and is relying only upon the Disclosure Package and the documents incorporated by
reference therein.

 

4.2 
(a) No action has been or will be taken in any jurisdiction outside the United States by the Company that would permit an offering
of the Shares, or possession or distribution of offering materials in connection with the issue of the Shares in any jurisdiction
outside the United States where action for that purpose is required, (b) if the Investor is outside the United States, it
will comply with all applicable laws and regulations in each foreign jurisdiction in which it purchases, offers, sells or
delivers Shares or has in its possession or distributes any offering material, in all cases at its own expense and (c) the Company
has not authorized anyone to make and has not made any representation, disclosure or use of any information in connection with
the issue, placement, purchase and sale of the Shares, except as set forth or incorporated by reference in the base prospectus,
the prospectus supplement or any free writing prospectus.

 

4.3 If
the Investor is an officer or director of the Company, or more than 10% shareholder in the Company, the Investor acknowledges and
agrees that the Shares delivered may be deemed to be “control securities” under Rule 144 promulgated under the Securities
Act and, accordingly, the resale of the Shares may be restricted under Rule 144 and the Shares may be subject to a restrictive
legend under the Securities Act. Such Investor shall comply with any insider trading policy adopted by the Company from time to
time covering transactions in the Company’s securities by employees, officers or directors of the Company. The Investor agrees
not to sell or otherwise dispose of the Shares in any manner which would constitute a violation of any applicable federal or state
securities laws.

 

4.4 (a)
The Investor has full right, power, authority and capacity to enter into this Agreement and to consummate the transactions contemplated
hereby and has taken all necessary action to authorize the execution, delivery and performance of this Agreement, and (b)
this Agreement constitutes a valid and binding obligation of the Investor enforceable against the Investor in accordance with
its terms, except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws
affecting creditors’ and contracting parties’ rights generally and except as enforceability may be subject to general
principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law) and except
as to the enforceability of any rights to indemnification or contribution that may be violative of the public policy underlying
any law, rule or regulation (including any federal or state securities law, rule or regulation).

 

    Annex - 2

     

    

 

4.5 The
Investor understands that nothing in this Agreement or the Disclosure Package, or any other materials presented to the Investor
in connection with the purchase and sale of the Shares constitutes legal, tax or investment advice. The Investor has consulted
such legal, tax and investment advisors and made such investigation as it, in its sole discretion, has deemed necessary or appropriate
in connection with its purchase of Shares.

 

5. Representations,
Warranties and Covenants of the Company.

 

The Company acknowledges, represents and warrants
to, and agrees with, the Investors that:

 

5.1 The
Company is a corporation duly organized, validly existing and in good standing under the laws of the State of Oregon and has full
corporate power and authority to own and use its properties and its assets and conduct its business as currently conducted. The
Company is not in violation of any of the provisions of its Second Amended and Restated Articles of Incorporation, as may be amended
from time to time (the “Restated Articles”), or its Amended and Restated By-laws (the “Bylaws”)
or other organizational or charter documents. The Company is duly qualified to conduct business and is in good standing as a foreign
corporation in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification
necessary, except where the failure to be so qualified or in good standing, as the case may be, would not result in a direct and/or
indirect (i) material adverse effect on the legality, validity or enforceability of any of the Shares and/or this Agreement, (ii)
material adverse effect on the results of operations, assets, business or condition (financial and other) of the Company, or (iii)
material adverse effect on the Company’s ability to perform in any material respect on a timely basis its obligations under
this Agreement (any of (i), (ii) or (iii), a “Material Adverse Effect”).

 

5.2 The
Company has prepared and filed in conformity with the requirements of the Securities Act of 1933, as amended (the “Securities
Act”), and published rules and regulations thereunder adopted by the SEC, a “shelf” registration statement
on Form S-3 (File No. 333-227683), which became effective on October 17, 2018, including a base prospectus relating to the securities
registered pursuant to such registration statement, and such amendments and supplements thereto as may have been required to the
date of this Agreement, including but not limited to, the preliminary prospectus supplement dated November 16, 2018.

 

5.3 All
of the issued and outstanding shares of capital stock of the Company are validly issued, fully paid and nonassessable. All of such
outstanding capital stock has been issued in compliance with applicable federal and state securities laws. The issuance and sale
of the Shares as contemplated hereby will not obligate the Company to issue shares of common stock or other securities to any other
person (other than the Investors) and will not result in the adjustment of the exercise, conversion, exchange or reset price of
any outstanding security.

 

    Annex - 3

     

    

 

5.4 The
Company has all corporate right, power and authority to enter into, execute and deliver this Agreement and each other agreement,
document, instrument and certificate to be executed by the Company in connection with the consummation of the transactions contemplated
hereby and to perform fully its obligations hereunder and thereunder. This Agreement has been duly executed and delivered by the
Company and constitutes a legal, valid and binding obligation of the Company, enforceable against the Company in accordance with
its terms, except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws
affecting creditors’ and contracting parties’ rights generally and except as enforceability may be subject to general
principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law) and except
as to the enforceability of any rights to indemnification or contribution that may be violative of the public policy underlying
any law, rule or regulation (including any federal or state securities law, rule or regulation). The Shares are duly authorized
and, when issued and paid for in accordance with the applicable transaction documents, will be duly and validly issued, fully paid
and nonassessable, free and clear of all encumbrances.

 

5.5 The
execution and delivery by the Company of this Agreement and the issuance and sale of the Shares do not and will not (i) result
in the violation of any law, statute, rule, regulation, order, writ, injunction, judgment or decree of any court or governmental
authority to or by which the Company is bound including without limitation all foreign, federal, state and local laws applicable
to its business and all such laws that affect the environment, except in each case as could not have or reasonably be expected
to result in a Material Adverse Effect, (ii) conflict with or violate any provision of the Company’s Restated Articles or
the Company’s Bylaws, and (iii) conflict with, or result in a material breach or violation of, any of the terms or provisions
of, or constitute (with or without due notice or lapse of time or both) a default or give to others any rights of termination,
amendment, acceleration or cancellation (with or without due notice, lapse of time or both) under any agreement, credit facility,
lease, loan agreement, mortgage, security agreement, trust indenture or other agreement or instrument to which the Company is a
party, nor result in the creation or imposition of any encumbrances upon any of the properties or assets of the Company, except
in each case as could not have or reasonably be expected to result in a Material Adverse Effect.

 

5.6 No
approval by the holders of the Company’s common stock or other equity securities of the Company is required to be obtained
by the Company in connection with the authorization, execution, delivery and performance of this Agreement or in connection with
the authorization, issue and sale of the Shares.

 

5.7 No
consent, approval, authorization or other order of any governmental authority or any other third party is required to be obtained
by the Company in connection with the authorization, execution, delivery and performance of this Agreement or in connection with
the authorization, issue and sale of the Shares, except for such post-sale filings as may be required to be made with the NASDAQ
Capital Market, the SEC and with any state securities regulatory authority, all of which shall be made when required.

 

6. Survival
of Representations, Warranties and Agreements; Third Party Beneficiary.

 

Notwithstanding any investigation made
by any party to this Agreement, all covenants, agreements, representations and warranties made by the Company and the Investor
herein will survive the execution of this Agreement, the delivery to the Investor of the Shares being purchased and the payment
therefor.

 

    Annex - 4

     

    

 

7. Notices.
All notices or other communications hereunder will be either (i) given in writing and delivered in person, (ii) sent by facsimile,
(iii) sent by electronic mail, (iv) sent by overnight courier or (v) sent by registered or certified mail, postage prepaid, return
receipt requested, to the parties at the following address:

 

		(a)	if to the Company, to:

                                                                  

                                                                 Arcimoto, Inc.

2034 West 2nd Avenue

Eugene, Oregon 97402

Attention: Karen Bacon, Controller

Email: investor@arcimoto.com

 

with a copy (which shall not constitute notice) to:

 

Wyrick Robbins Yates & Ponton LLP

4101 Lake Boone Trail, Suite 300

Raleigh, NC 27607

Attention: W. David Mannheim

Fax: (919) 781-4865

Email: wmannheim@wyrick.com

 

(b) if
to the Investor, at its address on the Signature Page hereto, or at such other address or addresses as may have been furnished
to the Company in writing.

 

Notice shall be deemed given on (a) the
date such notice is personally delivered, (b) three (3) days after the mailing if sent by certified or registered mail,
(c) one (1) business day after the date of delivery to the overnight courier if sent by overnight courier, or (d) the
date such notice is transmitted by facsimile or electronic mail, if such transmission is prior to 5:00 p.m. Pacific Time on
a business day, or the next succeeding business day if such transmission is later.

 

8. Changes.
This Agreement may not be modified or amended except pursuant to an instrument in writing signed by the Company and the
Investor.

 

9. Headings.
The headings of the various sections of this Agreement have been inserted for convenience of reference only and will not
be deemed to be part of this Agreement.

 

10. Severability.
In case any provision contained in this Agreement should be invalid, illegal or unenforceable in any respect, the validity,
legality and enforceability of the remaining provisions contained herein will not in any way be affected or impaired thereby.

 

11. Governing
Law. This Agreement will be governed by, and construed in accordance with, the internal laws of the State of Oregon,
without giving effect to the principles of conflicts of law that would require the application of the laws of any other jurisdiction.

 

12. Counterparts.
This Agreement may be executed in two or more counterparts, each of which will constitute an original, but all of which, when
taken together, will constitute but one instrument, and will become effective when one or more counterparts have been signed by
each party hereto and delivered to the other parties. The Company and the Investor acknowledge and agree that the Company shall
deliver its counterpart to the Investor.

 

13. Confirmation
of Sale. The Investor acknowledges and agrees that such Investor’s receipt of the Company’s signed counterpart
to this Agreement, shall constitute written confirmation of the Company’s sale of the Shares to such Investor.

 

    Annex - 5November
16, 2018

 

Glenn
Miles

 

RE:
Employment Agreement with Cancer Genetics, Inc.

 

Dear
Glenn,

 

On
behalf of Cancer Genetics, Inc. (“CGI or the Company”), I would like to take the opportunity to offer you the full-time
position of Chief Financial Officer, effective November 26, 2018, reporting to Jay Roberts, CEO. Your employment agreement will
be under the following terms:

 

Salary -
$11,538.46 bi-weekly (26 Pay periods per year), or $300,000.00 annualized, subject to the approval of our
Compensation Committee.

 

Terms – The employment contract shall begin on the effective date stated above, for a twelve-month period, and will automatically
extend for one year periods unless terminated by giving you a 60 day notice prior to the expiration of the agreement, or as otherwise
agreed upon.

 

Bonus - You will have the opportunity to earn additional compensation based on our bonus program with an annual target of up
to 30% of your annual base pay to be paid pro-rata for 2018 and 2019. The bonus will be paid out based on the condition
that the agreed upon performance goals are met.

 

Equity
Compensation – The Company will award you Restricted Stock Options which will begin vesting after one year of Board
Approval and vest in equal monthly increments over 48 months. You will receive 100,000 in Stock Options, and subject to formal
approval by the Board of Directors.

 

Benefits - Eligibility for participation in health, dental, vision, life insurance, and disabilities coverage, as well as participation
in the company 401(K) retirement plan, is the first of the month following your date of hire.

 

PTO
and Company Holidays - You will be eligible to accrue Paid Time Off (PTO) equivalent of 18 days for full calendar year.
Additional information may be found in the PTO Policy, which you will receive during your boarding process.

 

Cancer
Genetics provides 6 Company-paid holidays and 1 Floating Holiday per quarter in 2018.

 

Separation
Pay - In the event that your employment with the Company is terminated at the Company’s option, you will be entitled
to 6 months of severance or separation pay. For purposes of clarification, a termination at the Company’s option, at any
time, due to your failure to substantially perform the duties of the position of Chief Financial Officer, shall not entitle you
to a severance or separation payment.

 

Professional
Development – Cancer Genetics, Inc. is dedicated to our core values of knowledge and innovation and towards building
a Company that is aware and utilizes industry best practices. To ensure the Company’s industry position we are committed
to the professional development of our colleagues and executive management. You will be expected to maintain your Certified Public
Accountant (CPA) licensing, for which the associated costs will be reimbursed to you by the Company. You will be expected to monitor,
measure, and manage industry best practices through professional associations and industry conferences and apply key best-practices
to the CGI business and to your team’s knowledge base and processes.

 

201
Route 17 North, 2nd Floor, Rutherford, NJ 07070

www.cancergenetics.com

 

    	 	 	 

    	 

    

 

 

Your
employment with the Company is at-will and neither this letter nor any other oral or written representations may be considered
a contract of employment for any specific period of time. We recognize that you retain the option, as does the Company, to end
the employment relationship at any time for any lawful reason or no reason, with or without notice. Your status as an at-will
employee cannot be changed or modified except in a written agreement signed by you and the Company’s CEO.

 

Your
employment is contingent upon a positive background review and employment history screening typical for a position at CGI. Upon
your acceptance of this offer, you will be provided with the Company’s Employment Manual and the Code of Business Conduct
and Ethics. Your employment is also contingent upon the return of your signed acknowledgement of receipt of these documents, and
agreement to the terms in both of these documents which are incorporated by reference herein.

 

On
your first day, you will be completing employment forms, please bring appropriate documentation for the completion of your
new hire forms, including proof that you are presently eligible to work in the United States for I-9 purposes.

 

I
am genuinely excited about you joining our team, and expect that Cancer Genetics will be greatly strengthened as a result of your
contributions. If you have any questions about this offer letter, please feel free to contact me.

 

If
the above terms and statements meet with your approval, please sign this letter in the spaces provided below to reflect your acceptance.

 

Sincerely,

 

 

John
A. Roberts

Chief
Executive Officer

 

Offer
Acceptance:

 

I
have read this offer of employment, understand it, and accept the offer on these terms. I understand that my employment is contingent
upon receiving acceptable verification of required pre-employment screening, in addition to the requirements listed above. This
offer of employment expires on November 16, 2018.

 

	/s/
    Glenn Miles	 
	Glenn
    Miles	 

 

201
Route 17 North, 2nd Floor, Rutherford, NJ 07070

www.cancergenetics.com

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00289-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00289-of-00352.parquet"}]]